Etiqueta: adult stem cells

Celgene Cellular Therapeutics receives FDA authorization to commence the first clinical trials ever to be conducted in the U.S. with adult stem cells derived from placental blood.

Opexa Therapeutics is scheduled to present an overview of its T-cell and adult stem cell therapies for autoimmune diseases at an annual health care conference.

The biotech company Pluristem Therapeutics has developed an adult stem cell product for the prevention of clinical symptoms of multiple sclerosis.

The biotech company Pluristem Therapeutics Inc., specializing in adult stem cells, has been chosen to present at the First Annual Israeli Presidential Conference.

An intercultural consortium of researchers from across the European Union issues the first report identifying neural stem cells in the adult human spinal cord.

The biotech company Pluristem Therapeutics Inc. has found improvement in an animal model of multiple sclerosis with the use of a therapeutic product developed from mesenchymal stromal cells.

Scientists, doctors, patients and lawmakers work together to draft a state law that would expedite the storage and therapeutic administration of umbilical cord blood stem cells.

Stem Cells derived from umbilical cord blood are found to slow the progression of Alzheimer’s disease in mice.

A 24-year-old Canadian with MS shows significant improvement after being rescued with her own adult stem cells following chemotherapy treatment.

In an unusually amiable mixture of politics and science, researchers who are working with adult stem cells, and patients who have been successfully treated with adult stem cell therapy, appeared before members of Congress.